Jacobs & Co. CA reduced its holdings in Becton Dickinson and Co (NYSE:BDX) by 2.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 31,520 shares of the medical instruments supplier’s stock after selling 650 shares during the quarter. Jacobs & Co. CA’s holdings in Becton Dickinson and were worth $6,747,000 at the end of the most recent quarter.
A number of other hedge funds have also modified their holdings of BDX. BlackRock Inc. grew its stake in Becton Dickinson and by 6.0% in the fourth quarter. BlackRock Inc. now owns 18,811,302 shares of the medical instruments supplier’s stock valued at $4,026,750,000 after acquiring an additional 1,071,288 shares during the period. State Street Corp grew its stake in Becton Dickinson and by 3.5% in the second quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock valued at $2,003,834,000 after acquiring an additional 342,873 shares during the period. Bank of New York Mellon Corp grew its stake in Becton Dickinson and by 1.4% in the fourth quarter. Bank of New York Mellon Corp now owns 2,010,236 shares of the medical instruments supplier’s stock valued at $430,312,000 after acquiring an additional 26,956 shares during the period. Mawer Investment Management Ltd. grew its stake in Becton Dickinson and by 1.4% in the third quarter. Mawer Investment Management Ltd. now owns 1,799,828 shares of the medical instruments supplier’s stock valued at $352,599,000 after acquiring an additional 24,761 shares during the period. Finally, Findlay Park Partners LLP grew its stake in Becton Dickinson and by 2.3% in the third quarter. Findlay Park Partners LLP now owns 1,765,000 shares of the medical instruments supplier’s stock valued at $345,852,000 after acquiring an additional 40,000 shares during the period. Institutional investors and hedge funds own 77.50% of the company’s stock.
Becton Dickinson and Co (BDX) opened at $219.82 on Wednesday. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.54 and a quick ratio of 0.93. Becton Dickinson and Co has a 1 year low of $175.66 and a 1 year high of $248.39. The firm has a market capitalization of $59,337.46, a price-to-earnings ratio of 167.80, a price-to-earnings-growth ratio of 1.59 and a beta of 1.12.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.41 by $0.07. Becton Dickinson and had a return on equity of 16.19% and a net margin of 2.71%. The business had revenue of $3.08 billion for the quarter, compared to analysts’ expectations of $3.05 billion. During the same quarter in the previous year, the firm earned $2.33 earnings per share. The business’s revenue was up 5.4% on a year-over-year basis. equities analysts expect that Becton Dickinson and Co will post 10.94 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 30th. Shareholders of record on Friday, March 9th will be given a $0.75 dividend. The ex-dividend date is Thursday, March 8th. This represents a $3.00 annualized dividend and a yield of 1.36%. Becton Dickinson and’s dividend payout ratio is currently 229.01%.
In other Becton Dickinson and news, Director Timothy M. Ring sold 269,661 shares of the business’s stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $217.82, for a total value of $58,737,559.02. Following the transaction, the director now owns 295,753 shares of the company’s stock, valued at $64,420,918.46. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.00% of the stock is currently owned by insiders.
Several research analysts recently issued reports on BDX shares. Zacks Investment Research cut Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Friday, January 12th. Morgan Stanley lifted their target price on Becton Dickinson and from $205.00 to $245.00 and gave the company an “equal weight” rating in a research report on Friday, November 3rd. Royal Bank of Canada reaffirmed a “hold” rating and set a $210.00 target price on shares of Becton Dickinson and in a research report on Wednesday, October 25th. Stifel Nicolaus reaffirmed a “buy” rating and set a $245.00 target price on shares of Becton Dickinson and in a research report on Friday, November 3rd. Finally, KeyCorp started coverage on Becton Dickinson and in a research report on Friday, January 5th. They set an “overweight” rating and a $260.00 target price on the stock. Four investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $237.27.
COPYRIGHT VIOLATION NOTICE: “Becton Dickinson and Co (BDX) Shares Sold by Jacobs & Co. CA” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/21/becton-dickinson-and-co-bdx-shares-sold-by-jacobs-co-ca.html.
Becton Dickinson and Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.